A Phase 3 interventional study of Bupivacaine liposome injectable suspension 266 mg and Bupivacaine HCl in Bunionectomy and Hallux Valgus, sponsored by Pacira Pharmaceuticals, Inc. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-26.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Hallux Valgus with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Hallux Valgus · United States.
Among the 32 studies in Hallux Valgus with a site in United States, this one is the 6th largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2022, is one of 5 in phase 3, and was the 23rd registered.
157 studies on the registry are indexed under Hallux Valgus; 36 are open to participants now.
Browse Hallux Valgus studies →5 of the 32 studies in Hallux Valgus with a site in United States are open now. Recruiting first, the newest first:
DePuy Synthes Products, Inc. · Sites in United States
Ages 22+
Rebel Medicine Inc · Sites in United States
Ages 18+
Treace Medical Concepts, Inc. · Sites in United States
Ages 14–65 · Healthy volunteers
Arthrex, Inc. · Sites in United States, Germany, South Africa
Ages 2+ · Healthy volunteers
The International FOP Association · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Hallux Valgus studies recruiting now, 10 (48%) set no upper age limit and 7 (33%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 7
First in 2002; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 185 is above the median of 58 across 119 interventional studies indexed under Hallux Valgus.
Median enrollment 86 across the 24 interventional studies, 61 across the 8 observational. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 32 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 17 (63%) have results posted.
Pacira BioSciences, Inc. has 2 studies filed under Hallux Valgus — fewer than ten, so there is no comparison to draw.
1 of the studies in Hallux Valgus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05587569Treace Medical Concepts, Inc.Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Hallux Valgus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is conducted sequentially in two parts.
Part A: The purpose is to obtain information on pharmacokinetic (PK) profile, pharmacodynamics (PD), efficacy, safety, and to assess the performance of 266 mg EXPAREL vs 133 mg EXPAREL.
Part B: The purpose is to evaluate the efficacy and safety of the preferred dosage of EXPAREL from Part A compared with bupivacaine HCl.
This is a Phase 3, multicenter, randomized, double-blind, active controlled study in approximately 180 subjects undergoing bunionectomy. The study will be conducted in two parts (Part A and Part B). Part A will be completed and analyzed before enrollment in Part B is initiated.
Subjects may be screened up to 45 days prior to the day of surgery but eligibility must be re-confirmed on the day of surgery prior to randomization.
The following screening procedures will be performed after the informed consent form (ICF) is signed (if not standard of care): assess eligibility, record medical/surgical history, record prior and concomitant medications, record demographics and baseline characteristics, record subject height and weight for body mass index (BMI) calculation, assess chronic opioid use in the past 30 days, conduct urine pregnancy test for women of childbearing potential, perform 12-lead EKG, record serious adverse events (SAEs) starting when the ICF is signed, and record medications for treatment of SAEs.
On Day 1, prior to sciatic nerve block, study staff will review Pain Rating Guide with the subject and record their responses to:
Part A will enroll approximately 60 subjects undergoing bunionectomy into 1 of 3 arms. They will be randomized 1:1:1 to either EXPAREL 266 mg, EXPAREL 133 mg, or 0.25% bupivacaine HCl (50mg). Part A subjects will be asked to perform sensory function assessments, perform motor function assessments and obtain PK samples. Based on the findings of the interim analysis after completion of Part A, the study may stop for futility or proceed to Part B. Part B is a 2-arm study with 120 subjects being randomized 1:1 to either the better performing dosage of EXPAREL from Part A (266mg or 133mg) or 0.25% bupivacaine HCl (50mg).
All eligible subjects will receive Celecoxib 200 mg, orally (PO) pre-operatively within four hours prior to surgery.
Part A: On Day 1, Subjects will be randomized (1:1:1) to receive a sciatic (in the popliteal fossa) nerve block with a single dose of either: EXPAREL 266 mg, EXPAREL 133 mg, or 0.25% bupivacaine HCl (50 mg).
Part B: will continue enrolling with one of the EXPAREL arms (EXPAREL 266 mg arm or EXPAREL 133 mg arm) and the bupivacaine HCl arm. Therefore, the EXPAREL study arm that fails to show efficacy (conditional power less than 30% in the Part A analysis) will be dropped and the study will continue with two study arms. The final analysis will include subjects from both Part A and Part B.
If the conditional power of one EXPAREL arm is less than 30% and the other EXPAREL arm is greater than or equal to 30%:
If both EXPAREL arms have a conditional power greater than or equal to 30%:
If the conditional power of both treatment arms is less than 30%:
All subjects will receive a dose of 1000 mg of intravenous (IV) acetaminophen at the time of surgical incision. All subjects will receive one post-operative dose of 1000 mg IV acetaminophen, administered approximately 8 hours after the first dose (approximately 8 hours after incision). The maximum total dose will not exceed 2000 mg. No additional acetaminophen is permitted after the second IV acetaminophen dose.
Medications will be administered on an as needed (PRN) basis; opioids should not be given on a predetermined schedule.
After 96 hours, the analgesic regimen may be adjusted for each subject individually as deemed appropriate by the physician responsible for postsurgical care.
NRS Pain intensity scores (for pain experiencing in operative foot right now, for the worst pain experienced in the operative foot in the last 24 hours, and for the average pain in the operative foot in the last 24 hours) will be asked from the end of surgery to 96 hours post-surgery at designated timepoints.
Subjects in Part A and Part B will be discharged after the completion of the 168h and 96h assessments, respectively.
For the assessment of adverse events (AEs), SAEs, and concomitant medication use, a follow-up phone call will be made on Post Surgery Day (POD) 14 (±3 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subjects randomized to this treatment arm will receive 20 mL (266 mg) EXPAREL mixed with 10 mL saline
Drug: Bupivacaine liposome injectable suspension 266 mg
subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL mixed with 20 mL saline
Drug: Bupivacaine liposome injectable suspension 133 mg
Subjects randomized to this treatment arm will receive 20 mL (50 mg) 0.25% bupivacaine HCl mixed with 10 mL saline
Drug: Bupivacaine HCl
Subjects randomized to this treatment arm will receive 20 mL (266 mg) EXPAREL mixed with 10 mL saline OR 10 mL (133 mg) EXPAREL mixed with 20 mL saline. Dose will be determined following interim analysis of Part A.
Drug: Bupivacaine liposome injectable suspension 133 mg
subjects randomized to this treatment arm will receive 20 mL (50 mg) 0.25% bupivacaine HCl mixed with 10 mL saline
Drug: Bupivacaine HCl
Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg
Also known as: EXPAREL
Sciatic nerve block in the popliteal fossa with Bupivacaine HCl
Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg
Also known as: EXPAREL
NRS Pain Scores Through 96 Hours Post-surgery
The numeric rating scale pain intensity scores ranging from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, from 0 to 96 hours post-surgery. For each subject, the area under the curve was derived using the trapezoidal rule on the pain scores adjusted for opioid pain medication using the observed and imputed values. Area under the curve started with the first pain assessment obtained after surgery and use all subsequent pain assessments up to 96 hours post-surgery. Pain scores were taken at 5 interval point 0 hours, 24 hours, 48 hours, 72 hours, and 96 hours. There were also unscheduled pain scores measured before opioid consumption also included in the area under the curve calculation. The area under the curve ranged from 0 to 960. Higher scores represent a worse outcome.
Time frame: 0- 96 hours post-surgery
Postsurgical Opioid Consumption Through 96 Hours Post-surgery
Total postsurgical opioid consumption in oral morphine equivalents (OMED) from 0 to 96 hours post-surgery
Time frame: 0 to 96 hours post-surgery
Opioid-free Subjects Through 96 Hours Post-surgery
Percentage of opioid-free subjects through 96 hours
Time frame: 0 to 96 hours post-surgery
First Opioid Consumption Post-surgery
Time to first opioid consumption post-surgery
Time frame: 0 to 96 hours post-surgery
NRS Pain Scores Post-surgery
Worst and average NRS pain intensity scores at 24h, 48h, 72h, and 96h from the end of surgery Worst and average pain intensity scores on a numeric rating scale ranging from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, from 0 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours. Mean scores at each timepoint are provided. The total range is 0 (no pain) to 10 (worst possible pain). Higher values on the scale represent worse outcome.
Time frame: 0-24 hours, 24-48 hours, 48-72 hours, and 72-96 hours post-surgery
Participants were recruited based on physician referral at 6 sites between February 2022 and April 2022 for Part A and between April 2022 and July 2022 for Part B. The first participant was enrolled on February 15, 2022 and the last participant was enrolled on July 18, 2022.
| Milestone | EXPAREL 266 mg Arm | EXPAREL 133 mg Arm | Bupivacaine HCl Arm |
|---|---|---|---|
| Started | 22 | 22 | 22 |
| Completed | 21 | 21 | 19 |
| Not completed | 1 | 1 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Failure to meet continuation criteria | 0 | 0 | 1 |
| Milestone | EXPAREL 266 mg Arm | EXPAREL 133 mg Arm | Bupivacaine HCl Arm |
|---|---|---|---|
| Started | 0 | 59 | 60 |
| Completed | 0 | 59 | 60 |
| Not completed | 0 | 0 | 0 |
The numeric rating scale pain intensity scores ranging from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, from 0 to 96 hours post-surgery. For each subject, the area under the curve was derived using the trapezoidal rule on the pain scores adjusted for opioid pain medication using the observed and imputed values. Area under the curve started with the first pain assessment obtained after surgery and use all subsequent pain assessments up to 96 hours post-surgery. Pain scores were taken at 5 interval point 0 hours, 24 hours, 48 hours, 72 hours, and 96 hours. There were also unscheduled pain scores measured before opioid consumption also included in the area under the curve calculation. The area under the curve ranged from 0 to 960. Higher scores represent a worse outcome.
| units on a scale*hours | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm |
|---|---|---|---|
| NRS Pain Scores Through 96 Hours Post-surgery | 342.3 ± 265.35 | 201.3 ± 180.05 | 377.4 ± 188.60 |
Total postsurgical opioid consumption in oral morphine equivalents (OMED) from 0 to 96 hours post-surgery
| milligrams oral morphine equivalents | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm |
|---|---|---|---|
| Postsurgical Opioid Consumption Through 96 Hours Post-surgery | 32.68 ± 96.768 | 15.41 ± 126.781 | 41.62 ± 83.925 |
Percentage of opioid-free subjects through 96 hours
| percentage of participants | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm |
|---|---|---|---|
| Opioid-free Subjects Through 96 Hours Post-surgery | 4.5 | 33.3 | 9.8 |
Time to first opioid consumption post-surgery
| hours | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm |
|---|---|---|---|
| First Opioid Consumption Post-surgery | 16.06 (12.32 to 20.57) | 20.27 (17.13 to 29.98) | 20.68 (19.28 to 24.40) |
Worst and average NRS pain intensity scores at 24h, 48h, 72h, and 96h from the end of surgery Worst and average pain intensity scores on a numeric rating scale ranging from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, from 0 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours. Mean scores at each timepoint are provided. The total range is 0 (no pain) to 10 (worst possible pain). Higher values on the scale represent worse outcome.
| units on a scale | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm |
|---|---|---|---|
| Worst pain at 24 hours | 6.0 ± 3.18 | 4.4 ± 3.13 | 5.3 ± 3.06 |
| Worst pain at 48 hours | 6.1 ± 2.49 | 4.4 ± 3.14 | 7.3 ± 2.22 |
| Worst pain at 72 hours | 4.3 ± 3.55 | 2.7 ± 2.87 | 6.1 ± 2.69 |
| Worst pain at 96 hours | 4.4 ± 3.68 | 2.8 ± 2.84 | 5.1 ± 2.81 |
| Average pain at 24 hours | 4.7 ± 2.60 | 2.8 ± 2.32 | 3.0 ± 2.58 |
| Average pain at 48 hours | 3.9 ± 2.74 | 2.9 ± 2.33 | 4.8 ± 2.01 |
| Average pain at 72 hours | 3.5 ± 3.19 | 1.8 ± 2.05 | 4.1 ± 2.19 |
| Average pain at 96 hours | 3.2 ± 3.14 | 1.7 ± 2.03 | 3.3 ± 2.10 |
Collected over Treatment-emergent adverse events were collected from the date and time on or after the start date and time of study drug administration through post-operative Day 14. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: EXPAREL 266 mg Arm | 0/22 (0%) | 1/22 (4.5%) | 13/22 (59.1%) |
| Part A + B: EXPAREL 133 mg Arm | 0/81 (0%) | 0/81 (0%) | 42/81 (51.9%) |
| Part A + B: Bupivacaine HCl Arm | 0/82 (0%) | 1/82 (1.2%) | 45/82 (54.9%) |
| Event | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm |
|---|---|---|---|
| PyrexiaGeneral disorders | 1/22 | 0/81 | 0/82 |
| HypertensionVascular disorders | 1/22 | 0/81 | 0/82 |
| Atrioventricular block second degreeCardiac disorders | 0/22 | 0/81 | 1/82 |
| Event | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm |
|---|---|---|---|
| NauseaGastrointestinal disorders | 9/22 | 13/81 | 19/82 |
| VomitingGastrointestinal disorders | 5/22 | 4/81 | 7/82 |
| ConstipationGastrointestinal disorders | 3/22 | 10/81 | 16/82 |
| HeadacheNervous system disorders | 1/22 | 8/81 | 4/82 |
| PruritusSkin and subcutaneous tissue disorders | 1/22 | 6/81 | 5/82 |
| DyspepsiaGastrointestinal disorders | 1/22 | 2/81 | 0/82 |
| HypoaesthesiaNervous system disorders | 1/22 | 0/81 | 0/82 |
Number of all participants for whom baseline characteristics were measured
| Age, Continuous(years) | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| Mean | 48.36 ± 10.896 | 50.15 ± 12.823 | 47.24 ± 11.950 | 48.65 ± 12.239 |
| Age, Customized(Participants) | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| <45 Years | 6 | 28 | 30 | 64 |
| Between 45 and 65 years | 16 | 45 | 47 | 108 |
| >=65 years | 0 | 8 | 5 | 13 |
| Sex: Female, Male(Participants) | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| Female | 21 | 74 | 68 | 163 |
| Male | 1 | 7 | 14 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| Hispanic or Latino | 10 | 26 | 32 | 68 |
| Not Hispanic or Latino | 12 | 55 | 50 | 117 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| White | 16 | 47 | 49 | 112 |
| Black/African American | 4 | 25 | 28 | 57 |
| Other | 2 | 9 | 5 | 16 |
| Region of Enrollment(participants) | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| United States | 22 | 81 | 82 | 185 |
| ASA classification(Participants) | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| ASA 1 | 14 | 39 | 54 | 107 |
| ASA 2 | 8 | 42 | 28 | 78 |
| Body Mass Index(Participants) | Part A: EXPAREL 266 mg Arm | Part A + B: EXPAREL 133 mg Arm | Part A + B: Bupivacaine HCl Arm | Total |
|---|---|---|---|---|
| <25 kg/m^2 | 8 | 21 | 24 | 53 |
| 25 to <30 kg/m^2 | 10 | 27 | 32 | 69 |
| ≥30 kg/m^2 | 4 | 33 | 26 | 63 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2022 to primary completion in Aug 2022, 6 months.
Results were first posted in Jun 2025, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine